ClinicalTrials.gg
CompletedNCT03255226Updated Aug 23, 2024Results posted

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload

A Phase 3 interventional study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 6 Months to 14 Years. Per ClinicalTrials.gov, last updated 2024-08-23.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
6 Months to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing tolvaptan in Heart Failure — none open to participants now, none under way, none of them phase 3. Tolvaptan · Heart Failure.

Enrollment
9th of 19
60 · median 60
Started
2018
the only one that year
Phase 3
4 of 19
none open now
Registered
18th of 19
by date
Lead sponsor
3 of 19
Otsuka Pharmaceutical Co., Ltd.

Among the 19 studies testing tolvaptan in Heart Failure, this one is the 9th largest by enrollment, is the only one that started in 2018, is one of 4 in phase 3, and was the 18th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

None of the 19 studies testing tolvaptan in Heart Failure is open now. The open studies under Heart Failure, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 6 Months to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing tolvaptan in Heart Failure as a file.
02

Study summary

To determine the efficacy, safety, and dose and regimen of tolvaptan in pediatric CHF patients with volume overload

03

Conditions studied

  • Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload

Browse trials for

04

Who can participate

Ages eligible
6 Months to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with volume overload despite having received any of the following diuretic therapies in whom sufficient effects cannot be expected even if the dose of the diuretics is increased or in whom the investigator or subinvestigator judges that increasing the dose of the diuretics is difficult due to concerns regarding electrolyte abnormalities or other side effects

    • Furosemide (oral administration) ≥0.5 mg/kg/day. Azosemide 30 mg and torasemide 4 mg will be calculated as equivalent to furosemide 20 mg.
    • Hydrochlorothiazide ≥2 mg/kg/day
    • Trichlormethiazide ≥0.05 mg/kg/day
    • Spironolactone ≥ 1 mg/kg/day
  • Patients capable of complaining of thirst. Patients unable to complain of thirst due to their young age can also be enrolled in the trial if strict management of fluid intake and excretion is conducted. However, even if such fluid management is possible, the patients in whom the investigator or subinvestigator judges that tolvaptan cannot be safely administered are to be excluded
  • Patients who can be hospitalized from at least 3 days before start of tolvaptan administration until 2 days after the final administration.

others

Exclusion criteria

Exclusion Criteria:

  • Patients whose volume overload status shows improvement during the screening period or pretreatment observation period
  • Patients who are unable to drink fluid (including patients who are unable to sense thirst)
  • Patients whose circulatory blood flow is suspected to be decreased
  • Patients with an assisted circulation apparatus
  • Patients with hypernatremia (serum or blood sodium concentration exceeding 145 mEq/L) others
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Tolvaptan

    Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.

    Drug: Tolvaptan

Interventions

  • Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.

06

What researchers measure

Primary outcomes

  1. Percentages of Subjects Whose Was Decreased by 1.7% or More Body Weight From Baseline

    The primary endpoint of this trial was the percentage of subjects whose body weight on the day after the third day of treatment with tolvaptan at the evaluation dose (the third day of administration at the evaluation dose) was decreased by 1.7% or more from the weight measured before breakfast (baseline) on the first day of the treatment period (the initial tolvaptan administration day), under the condition that the mean daily urine volume for the 3 days of treatment with tolvaptan at the evaluation dose was higher than the daily urine volume for the pretreatment observation period. The percentage of subjects as well as the exact 95% confidence interval (CI) based on binomial distribution were calculated.

    Time frame: Day after Day 3 at evaluation dose

Secondary outcomes

  1. Change Rate From Baseline in Daily Urine Volume

    Daily urine volume was measured for the time interval starting at urination (an instruction to urinate) after breakfast and ending at complete urination immediately before administration on the following day. Baseline was 100% and the change rate was calculated like this. Percent change (%) = (\[daily urine volume on the Day1, Day2 and Day3 of the tolvaptan at the evaluation dose\] - \[daily urine volume on baseline\] ) / \[daily urine volume on baseline\] ×100

    Time frame: Baseline, Day1, Day2 and Day3 of administration at evaluation dose

  2. Percent Changes From Baseline in Body Weight (kg)

    Percent change from baseline in body weight (kg) on the day after the third day of treatment with tolvaptan at the evaluation dose was evaluated. For body weight measured on the day after the third day of administration at the evaluation dose, their percent changes from baseline (before the start of tolvaptan administration on the first day of the treatment period) mean and standard deviation (SD) were calculated. Baseline was 100% and the change rate was alculated like this. Percent change (%) = (\[body weight on the day after the third day of treatment with tolvaptan at the evaluation dose\] - \[body weight on baseline\] ) / \[body weight on baseline\] ×100

    Time frame: Day after Day 3 at evaluation dose

  3. Improvement Rates of Lower Limb Edema

    The improvement rate was defined as the percentage of subjects in whom a symptom was present at baseline and then markedly improved or improved after IMP administration. Improvement category is a 4-point scale below: * Markedly improved * Improved * Unchanged * Deteriorated

    Time frame: Day after Day 3 at evaluation dose

  4. Improvement Rates of Pulmonary Congestion

    The improvement rate was defined as the percentage of subjects in whom a symptom was present at baseline and then markedly improved or improved after IMP administration. Improvement category is a 4-point scale below: * Markedly improved * Improved * Unchanged * Deteriorated

    Time frame: Day after Day 3 at evaluation dose

07

Results

Posted Aug 23, 2024

Participant flow

Participant flow — Overall Study
MilestoneTolvaptan
Started60
Completed46
Not completed14
Withdrew: Adverse event2
Withdrew: Physician decision3
Withdrew: Withdrawal by subject1
Withdrew: Serum or blood sodium increased4
Withdrew: Serum or blood potassium increased4

Outcome measures

PrimaryPercentages of Subjects Whose Was Decreased by 1.7% or More Body Weight From Baseline

The primary endpoint of this trial was the percentage of subjects whose body weight on the day after the third day of treatment with tolvaptan at the evaluation dose (the third day of administration at the evaluation dose) was decreased by 1.7% or more from the weight measured before breakfast (baseline) on the first day of the treatment period (the initial tolvaptan administration day), under the condition that the mean daily urine volume for the 3 days of treatment with tolvaptan at the evaluation dose was higher than the daily urine volume for the pretreatment observation period. The percentage of subjects as well as the exact 95% confidence interval (CI) based on binomial distribution were calculated.

Time frame:
Day after Day 3 at evaluation dose
Reported as:
Number · percentage of participants
Percentages of Subjects Whose Was Decreased by 1.7% or More Body Weight From Baseline
percentage of participantsTolvaptan
Percentages of Subjects Whose Was Decreased by 1.7% or More Body Weight From Baseline22.8 (12.7 to 35.8)
SecondaryChange Rate From Baseline in Daily Urine Volume

Daily urine volume was measured for the time interval starting at urination (an instruction to urinate) after breakfast and ending at complete urination immediately before administration on the following day. Baseline was 100% and the change rate was calculated like this. Percent change (%) = (\[daily urine volume on the Day1, Day2 and Day3 of the tolvaptan at the evaluation dose\] - \[daily urine volume on baseline\] ) / \[daily urine volume on baseline\] ×100

Time frame:
Baseline, Day1, Day2 and Day3 of administration at evaluation dose
Reported as:
Mean · percentage of urine volume (mL)
Change Rate From Baseline in Daily Urine Volume
percentage of urine volume (mL)Tolvaptan
Day 153.1 ± 52.9
Day 247.8 ± 43.3
Day 345.8 ± 29.3
SecondaryPercent Changes From Baseline in Body Weight (kg)

Percent change from baseline in body weight (kg) on the day after the third day of treatment with tolvaptan at the evaluation dose was evaluated. For body weight measured on the day after the third day of administration at the evaluation dose, their percent changes from baseline (before the start of tolvaptan administration on the first day of the treatment period) mean and standard deviation (SD) were calculated. Baseline was 100% and the change rate was alculated like this. Percent change (%) = (\[body weight on the day after the third day of treatment with tolvaptan at the evaluation dose\] - \[body weight on baseline\] ) / \[body weight on baseline\] ×100

Time frame:
Day after Day 3 at evaluation dose
Reported as:
Mean · percentage of body weight (kg)
Percent Changes From Baseline in Body Weight (kg)
percentage of body weight (kg)Tolvaptan
Percent Changes From Baseline in Body Weight (kg)-0.371 ± 2.470
SecondaryImprovement Rates of Lower Limb Edema

The improvement rate was defined as the percentage of subjects in whom a symptom was present at baseline and then markedly improved or improved after IMP administration. Improvement category is a 4-point scale below: * Markedly improved * Improved * Unchanged * Deteriorated

Time frame:
Day after Day 3 at evaluation dose
Reported as:
Number · percentage of participants
Improvement Rates of Lower Limb Edema
percentage of participantsTolvaptan
Improvement Rates of Lower Limb Edema68.6 (50.7 to 83.1)
SecondaryImprovement Rates of Pulmonary Congestion

The improvement rate was defined as the percentage of subjects in whom a symptom was present at baseline and then markedly improved or improved after IMP administration. Improvement category is a 4-point scale below: * Markedly improved * Improved * Unchanged * Deteriorated

Time frame:
Day after Day 3 at evaluation dose
Reported as:
Number · percentage of participants
Improvement Rates of Pulmonary Congestion
percentage of participantsTolvaptan
Improvement Rates of Pulmonary Congestion51.6 (33.1 to 69.8)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were collected from the start of IMP administration up to 16 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tolvaptan0/60 (0%)1/60 (1.7%)25/60 (41.7%)
Most frequent serious events
Most frequent serious events
EventTolvaptan
Cardiac failure chronicCardiac disorders1/60
Most frequent other events
Showing 10 of 29
Most frequent other events
EventTolvaptan
ThirstGeneral disorders4/60
AnaemiaBlood and lymphatic system disorders2/60
ConstipationGastrointestinal disorders2/60
Dry mouthGastrointestinal disorders2/60
VomitngGastrointestinal disorders2/60
PyrexiaGeneral disorders2/60
HyperkalaemiaMetabolism and nutrition disorders2/60
NeutropeniaBlood and lymphatic system disorders1/60
Cardiovascular insufficiencyCardiac disorders1/60
Erythema of eyelidEye disorders1/60

Baseline characteristics

The FAS included 59 of 60 subjects (98.3%) who received the IMP. One subject was excluded from the FAS because the subject received the IMP at least once, and discontinued the trial before the daily urine volume data on Day 1 were obtained.

Age, Continuous
Age, Continuous(years)Tolvaptan
Mean5.44 ± 5.03
Age, Customized
Age, Customized(Participants)Tolvaptan
Age group — 6 months to less than 2 years20
Age group — 2 years to less than 7 years16
Age group — 7 years to less than 15 years23
Sex: Female, Male
Sex: Female, Male(Participants)Tolvaptan
Female28
Male31
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tolvaptan
Asian59
Region of Enrollment
Region of Enrollment(participants)Tolvaptan
Japan59
08

Study locations

1 site
  • Kanto Region, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Jul 2021, 40 months.

Results were first posted in Aug 2024, 3 years 1 month after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 40 months is above that.

Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2017
First posted
Aug 21, 2017
StartActual
Mar 7, 2018
Primary completionActual
Jul 11, 2021
CompletionActual
Jul 15, 2021
Results first posted
Aug 23, 2024
Last update
Aug 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03255226
Responsible party
Sponsor
First posted
Aug 21, 2017
Start date
Mar 7, 2018
Primary completion
Jul 11, 2021
Completion
Jul 15, 2021
Results posted
Aug 23, 2024
Last update
Aug 23, 2024

Study contacts

Takehisa Matsumaru, Mr
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion